Randox Showcases New All-In-One Solution for Molecular Diagnostics at MEDLAB Middle East 2020
|
By LabMedica International staff writers Posted on 05 Feb 2020 |

Illustration
Randox Biosciences, a part of Randox Laboratories, (Crumlin, UK), showcased its new Vivalytic molecular diagnostic platform at MEDLAB Middle East, the largest medical laboratory exhibition and congress in the Middle East & North Africa (MENA) region.
Vivalytic is the newest offering from Randox Biosciences for the molecular diagnostic industry to test for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform, which is capable of both Hi-Plex and Lo-Plex testing, combines nucleic acid extraction, PCR amplification followed by a suite of detection methods in a fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required, making Vivalytic a unique space-saving, hygienic solution for molecular diagnostic testing.
Randox Biosciences also showcased its Evidence series of immunoassay analyzers that have been developed using its patented Biochip Array Technology, which includes multiplex protein immunoassays and multiplex nucleic acid arrays. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format. Additionally, Randox Quality Control highlighted its newly-launched Infectious Disease Serology Internal Quality Controls, which include Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more. All the samples are provided in a user-friendly, liquid ready-to-use format, thus significantly reducing preparation time and the risk of pipetting errors.
At this year’s MEDLAB Middle East, Randox Laboratories presented its RX series of clinical chemistry analyzers which feature robust hardware combined with intuitive software for ensuring precise and accurate results. Its extensive test menu delivers consolidation and can help to bring testing in house, reducing both costs and time. Additionally, Randox Laboratories showcased its wide range of reagents for advancing biochemistry testing for laboratories, including niche and superior performance assays which cover routine and novel markers. Applications are available detailing instrument-specific settings for the convenient use of Randox reagents on a wide range of clinical chemistry analyzers. Randox Laboratories also highlighted its range of complete QC solutions comprising true third-party controls for a wide range of testing, including molecular infectious diseases, inter-laboratory data management software and the world’s largest international EQA scheme – RIQAS.
Related Links:
Randox Laboratories
Vivalytic is the newest offering from Randox Biosciences for the molecular diagnostic industry to test for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform, which is capable of both Hi-Plex and Lo-Plex testing, combines nucleic acid extraction, PCR amplification followed by a suite of detection methods in a fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required, making Vivalytic a unique space-saving, hygienic solution for molecular diagnostic testing.
Randox Biosciences also showcased its Evidence series of immunoassay analyzers that have been developed using its patented Biochip Array Technology, which includes multiplex protein immunoassays and multiplex nucleic acid arrays. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format. Additionally, Randox Quality Control highlighted its newly-launched Infectious Disease Serology Internal Quality Controls, which include Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more. All the samples are provided in a user-friendly, liquid ready-to-use format, thus significantly reducing preparation time and the risk of pipetting errors.
At this year’s MEDLAB Middle East, Randox Laboratories presented its RX series of clinical chemistry analyzers which feature robust hardware combined with intuitive software for ensuring precise and accurate results. Its extensive test menu delivers consolidation and can help to bring testing in house, reducing both costs and time. Additionally, Randox Laboratories showcased its wide range of reagents for advancing biochemistry testing for laboratories, including niche and superior performance assays which cover routine and novel markers. Applications are available detailing instrument-specific settings for the convenient use of Randox reagents on a wide range of clinical chemistry analyzers. Randox Laboratories also highlighted its range of complete QC solutions comprising true third-party controls for a wide range of testing, including molecular infectious diseases, inter-laboratory data management software and the world’s largest international EQA scheme – RIQAS.
Related Links:
Randox Laboratories
Latest MEDLAB 2020 News
- Diagnostica Stago Displays STA Compact Max and STA Satellite Max Analyzers at MEDLAB
- DAS Srl Exhibits Range of Fully Automated Systems at MEDLAB Middle East 2020
- GeneMatrix Promotes Sex and Respiratory Infection Testing Products at MEDLAB
- Mindray Showcases Comprehensive IVD Solutions Portfolio at MEDLAB Middle East 2020
- New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020
- Vircell Exhibits Its New VirClia Lotus and qSPEED-OLIGO Systems at MEDLAB
- EKF Diagnostics Displays POC Analyzers for Hemoglobin, HbA1c And Lactate at MEDLAB Middle East
- Erba Mannheim Launches New Electrolyte Analyzer with Maintenance-free Electrodes at MEDLAB 2020
- MEDLAB Middle East 2020 Addresses Future of Laboratory Medicine
Channels
Clinical Chemistry
view channel
Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, with more than 60% of cases still diagnosed at a late stage. Uptake of existing screening tools remains suboptimal,... Read more
Automated NfL Assay Supports Monitoring of Neurological Disorders
Neuroaxonal injury occurs across a wide range of neurological disorders and remains difficult to monitor noninvasively over time. Blood-based measurement of neurofilament light chain (NfL) provides a biologically... Read moreMolecular Diagnostics
view channel
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more









